C16 Biosciences

c16bio.com →

-70%

est. 2Y upside i

Healthcare

Next-gen ingredients to decarbonize consumer products, starting w/…

Rank

#1610

Sector

Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Medium

C16 Biosciences presents a risky equity opportunity for a job seeker.

Last updated: March 10, 2026

Bull (20%)+300%

C16 Biosciences successfully expands its Palmless platform into the food & beverage sector, achieving FDA GRAS status and securing major partnerships with consumer goods manufacturers. This drives revenue to over $100M by 2028, justifying a $400M valuation at a healthy multiple, significantly above the current assumed $100M.

Base (50%)+50%

The company maintains its growth trajectory in beauty and personal care while making steady, albeit slower, progress in the food segment. Revenue grows to approximately $30M-$40M by 2028, leading to an exit valuation of around $150M, representing a moderate return for common shareholders.

Bear (30%)-80%

C16 Biosciences faces intense competition from well-funded rivals and struggles with the high capital intensity and regulatory hurdles of scaling food-grade products. Revenue growth stagnates, leading to a down round or an acquisition at a significantly lower valuation of $20M, wiping out most common stock value due to the severe liquidation preferences.

Est. time to liquidity~5.0 years

Preference Stack Risk

severe

Investors hold $34M in liquidation preferences ahead of common stock. In an exit at or below $100M, employees with common stock may get little or nothing.

Dilution Risk

high

As a Series A company with high capital intensity, C16 Biosciences will likely require several more funding rounds, leading to further dilution for existing equity holders.

Secondary Liquidity

none

There is currently no active secondary market or tender offers for C16 Biosciences' equity, typical for a company at this stage.

View all 2 open roles at C16 Biosciences →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on C16 Biosciences's data — designed to show you've done your homework.

  • 1

    “Given the significant capital intensity of biomanufacturing, how does C16 Biosciences plan to navigate future funding rounds to minimize dilution for common shareholders, especially with the existing preference stack?”

  • 2

    “With well-funded competitors like Zero Acre Farms and Air Protein, what is C16 Biosciences' differentiated strategy to capture significant market share in both the beauty & personal care and the nascent food & beverage segments?”

  • 3

    “What are the key milestones and anticipated timelines for achieving FDA GRAS status for your food-grade Palmless products, and how are you mitigating potential regulatory delays?”

Community

Valuation Sentiment

Our model estimates -70% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.